Phathom Pharmaceuticals, Inc. (PHAT) came out with a quarterly loss of $1.07 per share versus the Zacks Consensus Estimate of a loss of $1.06. This compares to loss of $1.42 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -0.94%. A quarter ago, it was expected that this company would post a loss of $0.98 per share when it actually produced a loss of $0.79, delivering a surprise of 19.39%.Over the last four quarters, the compan ...

Phathom Pharmaceuticals (PHAT) Q1 2025 Earnings Call May 01, 2025 08:00 AM ET Speaker0 Please be advised that today's conference is being recorded. With that, I would like to turn the conference over to Eric Schirrelli, Fathom's Head of Investor Relations. Please go ahead. Speaker1 Thank you, operator. Hello, everyone, and thank you for joining us this morning to discuss Fathom's first quarter twenty twenty five results. This morning's presentation will include remarks from Steve Bosta, our President and CE ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-39094 PHATHOM PHARMACEUTICALS, INC. Delaware 82-4151574 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer ...

Strategic Initiatives to Drive Topline Growth, Cost Reductions and Organizational Changes: Exhibit 99.1 Phathom Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update FLORHAM PARK, N.J., May 1, 2025 — Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today reported financial results for the first quarter ended March 31, 2025, and provided a business update ...

FLORHAM PARK, N.J., May 01, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today reported financial results for the first quarter ended March 31, 2025, and provided a business update, including strategic cost reductions and leadership changes to drive revenue growth and achieve profit from operations, excluding stock-based compensation, in 2026. "2025 will be an ...

Core Insights - Phathom Pharmaceuticals is set to present real-world data on its first-in-class treatment VOQUEZNA (vonoprazan) for gastroesophageal reflux disease (GERD) at Digestive Disease Week (DDW) from May 3-6, 2025, in San Diego, CA [1][3] - VOQUEZNA is the only treatment approved by the U.S. FDA for adults for heartburn relief associated with Non-Erosive GERD and for treating all severities of Erosive Esophagitis (Erosive GERD) [1][34] - The data presented will analyze treatment patterns and patient characteristics, indicating VOQUEZNA's potential role for patients inadequately managed by existing therapies [3] Company Activities - Two Phathom-sponsored posters will be presented on May 5, 2025, at the conference, along with a Product Theater highlighting VOQUEZNA [2] - The company will maintain a strong presence at the conference with a booth (1743) on the exhibit floor [2] Industry Context - GERD affects approximately 1 in 5 U.S. adults, with around 70% of the GERD population suffering from Non-Erosive GERD [31][32] - Erosive GERD, affecting about 30% of the GERD population, can lead to severe complications if inadequately treated [33] - The conference will showcase over 5,600 abstracts and hundreds of lectures on the latest advances in GI research, medicine, and technology [8]

Company Overview - Phathom Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases [3] - The company has in-licensed exclusive rights to vonoprazan, a first-in-class potassium-competitive acid blocker (PCAB) [3] - Vonoprazan is marketed in the U.S. as VOQUEZNA® for various gastrointestinal conditions, including Non-Erosive GERD and H. pylori infection [3] Upcoming Events - Management will host a live webcast on May 1, 2025, at 8:00 am EDT to report first quarter 2025 financial results and provide a business update [1] - Additional information and access to the webcast can be found on the Events & Presentations section of the Phathom website [2] - A recording of the webcast will be available for 90 days following the event [2]

FLORHAM PARK, N.J., April 03, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, announced today that members of the management team will participate in a fireside chat at the 24th Annual Needham Virtual Healthcare Conference on Tuesday, April 8th, 2025, at 10:15 am ET. Company management will also participate in one-on-one meetings during the conference, which will r ...

FLORHAM PARK, N.J., April 01, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today announced that, in connection with the appointment of Steven Basta as President and Chief Executive Officer, the Company's Board of Directors has approved the grant of inducement awards. The Board of Directors approved the grant to Mr. Basta of a non-qualified stock option to purch ...

FLORHAM PARK, N.J., April 01, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today announced that Steven Basta has been appointed President and Chief Executive Officer and a member of the Board of Directors, effective immediately. Mr. Basta succeeds Terrie Curran, who is stepping down as President and CEO and as a member of the Board of Directors for personal reas ...